研究目的
To assess progression-free survival (PFS), overall survival (OS), Karnofsky performance score (KPS), and steroid dependence as a function of LITT ablation volume/diameter for a relatively homogenous cohort of patients with biopsy-proven RN.
研究成果
PFS may increase with RVAs/RDAs in patients undergoing LITT for biopsy-proven RN. A radical ablation can be safe in non-eloquent areas and should thus be the goal for these patients. A prospective multicenter trial with a larger cohort is necessary to validate our findings.
研究不足
Single center, retrospective study including follow-up and selection bias. Sampling error can occur, and since LITT can be effective in treating neoplastic disease, PFS results may have confounding bias introduced. OS in a patient population with known metastatic disease is not a reliable primary outcome.
